141 related articles for article (PubMed ID: 23187004)
1. Synergistic inhibition of mesothelioma cell growth by the combination of clofarabine and resveratrol involves Nrf2 downregulation.
Lee YJ; Im JH; Lee DM; Park JS; Won SY; Cho MK; Nam HS; Lee YJ; Lee SH
BMB Rep; 2012 Nov; 45(11):647-52. PubMed ID: 23187004
[TBL] [Abstract][Full Text] [Related]
2. Synergistic anti-cancer effects of resveratrol and chemotherapeutic agent clofarabine against human malignant mesothelioma MSTO-211H cells.
Lee YJ; Lee YJ; Im JH; Won SY; Kim YB; Cho MK; Nam HS; Choi YJ; Lee SH
Food Chem Toxicol; 2013 Feb; 52():61-8. PubMed ID: 23146690
[TBL] [Abstract][Full Text] [Related]
3. Reactive oxygen species and PI3K/Akt signaling play key roles in the induction of Nrf2-driven heme oxygenase-1 expression in sulforaphane-treated human mesothelioma MSTO-211H cells.
Lee YJ; Jeong HY; Kim YB; Lee YJ; Won SY; Shim JH; Cho MK; Nam HS; Lee SH
Food Chem Toxicol; 2012 Feb; 50(2):116-23. PubMed ID: 22019695
[TBL] [Abstract][Full Text] [Related]
4. Resveratrol Attenuates the Cytotoxicity Induced by Amyloid-β
Hui Y; Chengyong T; Cheng L; Haixia H; Yuanda Z; Weihua Y
Neurochem Res; 2018 Feb; 43(2):297-305. PubMed ID: 29090409
[TBL] [Abstract][Full Text] [Related]
5. Resveratrol and clofarabine induces a preferential apoptosis-activating effect on malignant mesothelioma cells by Mcl-1 down-regulation and caspase-3 activation.
Lee YJ; Lee YJ; Lee SH
BMB Rep; 2015 Mar; 48(3):166-71. PubMed ID: 24924397
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of Bcl-xL enhances growth-inhibiting and apoptosis-inducing effects of resveratrol and clofarabine in malignant mesothelioma H-2452 cells.
Lee YJ; Hwang IS; Lee YJ; Lee CH; Kim SH; Nam HS; Choi YJ; Lee SH
J Korean Med Sci; 2014 Nov; 29(11):1464-72. PubMed ID: 25408576
[TBL] [Abstract][Full Text] [Related]
7. PM2.5 induces Nrf2-mediated defense mechanisms against oxidative stress by activating PIK3/AKT signaling pathway in human lung alveolar epithelial A549 cells.
Deng X; Rui W; Zhang F; Ding W
Cell Biol Toxicol; 2013 Jun; 29(3):143-57. PubMed ID: 23525690
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol contributes to chemosensitivity of malignant mesothelioma cells with activation of p53.
Lee YJ; Park IS; Lee YJ; Shim JH; Cho MK; Nam HS; Park JW; Oh MH; Lee SH
Food Chem Toxicol; 2014 Jan; 63():153-60. PubMed ID: 24239893
[TBL] [Abstract][Full Text] [Related]
9. Nrf2 Expression and Apoptosis in Quercetin-treated Malignant Mesothelioma Cells.
Lee YJ; Lee DM; Lee SH
Mol Cells; 2015 May; 38(5):416-25. PubMed ID: 25896339
[TBL] [Abstract][Full Text] [Related]
10. Resveratrol inhibits estrogen-induced breast carcinogenesis through induction of NRF2-mediated protective pathways.
Singh B; Shoulson R; Chatterjee A; Ronghe A; Bhat NK; Dim DC; Bhat HK
Carcinogenesis; 2014 Aug; 35(8):1872-80. PubMed ID: 24894866
[TBL] [Abstract][Full Text] [Related]
11. Piceatannol induces heme oxygenase-1 expression in human mammary epithelial cells through activation of ARE-driven Nrf2 signaling.
Lee HH; Park SA; Almazari I; Kim EH; Na HK; Surh YJ
Arch Biochem Biophys; 2010 Sep; 501(1):142-50. PubMed ID: 20558128
[TBL] [Abstract][Full Text] [Related]
12. Baicalein protects human vitiligo melanocytes from oxidative stress through activation of NF-E2-related factor2 (Nrf2) signaling pathway.
Ma J; Li S; Zhu L; Guo S; Yi X; Cui T; He Y; Chang Y; Liu B; Li C; Jian Z
Free Radic Biol Med; 2018 Dec; 129():492-503. PubMed ID: 30342186
[TBL] [Abstract][Full Text] [Related]
13. PI3K/Akt pathway mediates Nrf2/ARE activation in human L02 hepatocytes exposed to low-concentration HBCDs.
Zou W; Chen C; Zhong Y; An J; Zhang X; Yu Y; Yu Z; Fu J
Environ Sci Technol; 2013; 47(21):12434-40. PubMed ID: 24094245
[TBL] [Abstract][Full Text] [Related]
14. FGF9-induced changes in cellular redox status and HO-1 upregulation are FGFR-dependent and proceed through both ERK and AKT to induce CREB and Nrf2 activation.
Chuang JI; Huang JY; Tsai SJ; Sun HS; Yang SH; Chuang PC; Huang BM; Ching CH
Free Radic Biol Med; 2015 Dec; 89():274-86. PubMed ID: 26424114
[TBL] [Abstract][Full Text] [Related]
15. Flunarizine induces Nrf2-mediated transcriptional activation of heme oxygenase-1 in protection of auditory cells from cisplatin.
So HS; Kim HJ; Lee JH; Lee JH; Park SY; Park C; Kim YH; Kim JK; Lee KM; Kim KS; Chung SY; Jang WC; Moon SK; Chung HT; Park RK
Cell Death Differ; 2006 Oct; 13(10):1763-75. PubMed ID: 16485034
[TBL] [Abstract][Full Text] [Related]
16. Simvastatin induces heme oxygenase-1 via NF-E2-related factor 2 (Nrf2) activation through ERK and PI3K/Akt pathway in colon cancer.
Jang HJ; Hong EM; Kim M; Kim JH; Jang J; Park SW; Byun HW; Koh DH; Choi MH; Kae SH; Lee J
Oncotarget; 2016 Jul; 7(29):46219-46229. PubMed ID: 27323826
[TBL] [Abstract][Full Text] [Related]
17. Evidence that cisplatin-induced auditory damage is attenuated by downregulation of pro-inflammatory cytokines via Nrf2/HO-1.
So H; Kim H; Kim Y; Kim E; Pae HO; Chung HT; Kim HJ; Kwon KB; Lee KM; Lee HY; Moon SK; Park R
J Assoc Res Otolaryngol; 2008 Sep; 9(3):290-306. PubMed ID: 18584244
[TBL] [Abstract][Full Text] [Related]
18. Up-regulation of Nrf2-mediated heme oxygenase-1 expression by eckol, a phlorotannin compound, through activation of Erk and PI3K/Akt.
Kim KC; Kang KA; Zhang R; Piao MJ; Kim GY; Kang MY; Lee SJ; Lee NH; Surh YJ; Hyun JW
Int J Biochem Cell Biol; 2010 Feb; 42(2):297-305. PubMed ID: 19931411
[TBL] [Abstract][Full Text] [Related]
19. A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia.
Chiarini F; Lonetti A; Teti G; Orsini E; Bressanin D; Cappellini A; Ricci F; Tazzari PL; Ognibene A; Falconi M; Pagliaro P; Iacobucci I; Martinelli G; Amadori S; McCubrey JA; Martelli AM
Oncotarget; 2012 Dec; 3(12):1615-28. PubMed ID: 23271044
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of autophagy potentiates pemetrexed and simvastatin-induced apoptotic cell death in malignant mesothelioma and non-small cell lung cancer cells.
Hwang KE; Kim YS; Jung JW; Kwon SJ; Park DS; Cha BK; Oh SH; Yoon KH; Jeong ET; Kim HR
Oncotarget; 2015 Oct; 6(30):29482-96. PubMed ID: 26334320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
